Advertisement

Topics

Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)

2014-08-27 03:13:16 | BioPortfolio

Summary

The overall aim of this study is to develop a test that predicts the prognosis of IPF (Idiopathic Pulmonary Fibrosis) and which could be used to determine whether new treatments for IPF are likely to work.

Description

The overall objectives of this study are

- Discover and validate novel biomarkers and gene expression profiles for use in subsequent intervention studies in patients with IPF

- To prospectively validate a panel of previously published biomarkers in patients with well characterized idiopathic fibrosing lung disease

- Investigate genetic associations and epigenetic modifications which affect disease severity and progression

- Prospectively evaluate longitudinal disease behaviour in patients with IPF and NSIP with a view to developing composite clinical end-points for subsequent use in intervention studies in patients with IPF

Biomarkers that can be used for the following purposes will be identified:

- Identify patients (Diagnostic)(e.g. discriminate between health and disease)

- Correlate with disease severity (extent of disease, staging of disease)

- Predict clinical progression (Prognostic)(stable vs progressive disease)

- Track response to therapy (Theranostic)- Predict response to known efficacious treatments & Correlates with changes in clinical endpoints/mortality/quality of life

- Predict risk of exacerbations (could be used to prevent exacerbations or reduce their severity)

- Correlate with complications and/or comorbidities (e.g. biomarkers of PAH,GER in IPF, etc)

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Conditions

Idiopathic Pulmonary Fibrosis

Status

Not yet recruiting

Source

University of Nottingham

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:13:16-0400

Clinical Trials [2119 Associated Clinical Trials listed on BioPortfolio]

Pirfenidone for the Treatment of Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis (PF/IPF)

To assess the long-term safety and efficacy of oral pirfenidone in doses of up to 40 mg/kg/d in a limited number of patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF)

OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study

Descriptive prospective non-interventional multicenter study based on newly collected data of Idiopathic Pulmonary Fibrosis patients followed-up for one year in secondary care settings (Pu...

Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry

The purpose of this study is to create a database of demographics and samples in idiopathic pulmonary fibrosis.

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis. Bosentan (an oral dual ET-1 receptor antago...

Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis Using PET/CT

The investigators wish to evaluate the feasibility of [18F]FP-R01-MG-F2 PET/CT scanning in patients with Idiopathic Pulmonary Fibrosis.

PubMed Articles [4387 Associated PubMed Articles listed on BioPortfolio]

Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.

Current guidelines for the diagnosis of idiopathic pulmonary fibrosis (IPF) provide specific criteria for diagnosis in the setting of multidisciplinary discussion (MDD). We evaluate the utility and re...

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis.

Diabetes mellitus is a possible risk factor for the development of idiopathic pulmonary fibrosis (IPF), yet the effect of antidiabetic therapy on the course of IPF is unknown.

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated CT Analysis.

To determine whether computer-derived computed tomography measures, specifically measures of pulmonary vessel-related structures, can better predict functional decline and survival in idiopathic pulmo...

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.

Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary fibrosis (IPF), but treatment use remains at ∼60%.

Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis.

Gastroesophageal reflux (GER) is postulated to play a role in idiopathic pulmonary fibrosis (IPF). However, the value of objective GER measures in predicting IPF disease progression is unclear. We aim...

Medical and Biotech [MESH] Definitions

A group of interstitial lung diseases with no known etiology. There are several entities with varying patterns of inflammation and fibrosis. They are classified by their distinct clinical-radiological-pathological features and prognosis. They include IDIOPATHIC PULMONARY FIBROSIS; CRYPTOGENIC ORGANIZING PNEUMONIA; and others.

A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.

A form of CARDIAC MUSCLE disease in which the ventricular walls are excessively rigid, impeding ventricular filling. It is marked by reduced diastolic volume of either or both ventricles but normal or nearly normal systolic function. It may be idiopathic or associated with other diseases (ENDOMYOCARDIAL FIBROSIS or AMYLOIDOSIS) causing interstitial fibrosis.

A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.

Familial or idiopathic hypertension in the PULMONARY CIRCULATION which is not secondary to other disease.

More From BioPortfolio on "Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Epigenetics
The development and maintenance of an organism is orchestrated by a set of chemical reactions that switch parts of the genome off and on at strategic times and locations. Epigenetics is the study of these reactions and the factors that influence them. ...


Searches Linking to this Trial